Matrix metalloproteinase-2 and-9 in the sera and in the urine of human oncocytoma and renal cell carcinoma
Matrix metalloproteinase-2 and-9 in the sera and in the urine of human oncocytoma and renal cell carcinoma
复制标题
DOI：
10.3892/or.2012.1864
复制
发表时间：
2012-09-01
期刊：
影响因子：
4.2
通讯作者：
Di Carlo, Angelina
中科院分区：
文献类型：
--
作者：
Di Carlo, Angelina
基质金属蛋白酶 (MMP) 是锌依赖性内肽酶家族，能够降解细胞外基质的所有分子成分。 MMP 已被证明在肿瘤细胞侵袭和转移中发挥关键作用。我们通过明胶酶谱法验证了肾癌患者血清和尿液中 MMP 的活性。这些患者中，16 名患有透明细胞肾癌 (ccRCC)，4 名患者患有嗜酸细胞瘤。 16名健康受试者的血清和尿液作为对照。在血清中，酶谱分析显示在 72 kDa（明胶酶 A）、92、130 和 240 kDa（明胶酶 B）处有明胶分解条带。与嗜酸细胞瘤患者相比，ccRCC 血清中的 MMP-9 活性略有增强。 ccRCC 和嗜酸细胞瘤患者的血清 MMP-2 活性相似。在尿液中，2 名嗜酸细胞瘤患者和 3 名 ccRCC 患者（33%）表现出明胶溶解活性，而在健康受试者的浓缩尿液中无法检测到 MMP。最丰富的裂解活性为 92 kDa，而 MMP-2 的含量较少。然而，数据存在广泛重叠，我们没有发现与类型、阶段或年级有任何相关性。因此，尽管有先前的证据，血清和尿液中的 MMP-2 和 -9 活性可能不是肾癌的有用生物标志物。
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases, capable of degrading all the molecular components of extracellular matrix. MMPs have been shown to play critical roles in tumor cell invasion and metastasis. We verified the activity of MMPs in the sera and in the urine of patients with kidney carcinoma by gelatin zymography. Of these patients, 16 had clear cell renal carcinoma (ccRCC) and 4 patients had oncocytoma. The sera and the urine of 16 healthy subjects were used as controls. In the sera, zymography analysis showed gelatinolytic bands at 72 kDa (gelatinase A) at 92, 130 and 240 kDa (gelatinase B). MMP-9 activity was slightly enhanced in sera from ccRCC compared with oncocytoma patients. Serum MMP-2 activity was similar in ccRCC and in oncocytoma patients. In the urine, 2 oncocytoma patients and 3 (33%) of the ccRCC patients showed gelatinolytic activity, whereas MMPs could not be detected in the concentrated urine of healthy subjects. The most abundant lytic activity was at 92 kDa, whereas MMP-2 was present in lesser quantities. However, there was broad overlap of the data and we did not find any correlation to type, stage or grade. Therefore, despite previous evidence, MMP-2 and -9 activity in serum and urine may not be useful biomarker for kidney carcinomas.